These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Imaging in breast cancer - breast cancer imaging revisited. Mankoff D Breast Cancer Res; 2005; 7(6):276-8. PubMed ID: 16457704 [No Abstract] [Full Text] [Related]
49. Whole body imaging. Baur-Melnyk A Eur J Radiol; 2009 Jun; 70(3):381. PubMed ID: 19414232 [No Abstract] [Full Text] [Related]
51. State of the science of molecular imaging: 2008. Anderson CJ J Nucl Med; 2009 Feb; 50(2):16N-17N. PubMed ID: 19176332 [No Abstract] [Full Text] [Related]
52. [Focus on research hot point of medical imaging to promote its progress]. Zhang MM; Wu XY Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Mar; 39(2):113-7. PubMed ID: 20387236 [No Abstract] [Full Text] [Related]
53. Multimodality molecular imaging with combined optical and SPECT/PET modalities. Culver J; Akers W; Achilefu S J Nucl Med; 2008 Feb; 49(2):169-72. PubMed ID: 18199608 [TBL] [Abstract][Full Text] [Related]
54. Expert Opinion: which cardiothoracic imaging applications of PET/CT are most likely to be replaced by PET/MRI? Boiselle PM; Nensa F; Ohno Y; Torigian DA J Thorac Imaging; 2014 Jan; 29(1):3. PubMed ID: 24322909 [No Abstract] [Full Text] [Related]
55. Role of small animal PET in stimulating the development of new radiopharmaceuticals in oncology. Nanni C; Rubello D; Khan S; Al-Nahhas A; Fanti S Nucl Med Commun; 2007 Jun; 28(6):427-9. PubMed ID: 17460532 [No Abstract] [Full Text] [Related]
56. Neuroimaging of epilepsy: advances and practical applications. Kuzniecky RI Rev Neurol Dis; 2004; 1(4):179-89. PubMed ID: 16400279 [TBL] [Abstract][Full Text] [Related]
57. [Nuclear medicine imaging in neurodegenerative dementias]. Gratz S; Hahn U; Kaiser JW; Jarnig M; Schwarz J; Förstl H Dtsch Med Wochenschr; 2008 May; 133 Suppl 1():S5-7. PubMed ID: 18437639 [TBL] [Abstract][Full Text] [Related]
58. The unique potential for noninvasive imaging in modernizing drug development and in transforming therapeutics: PET/MRI/MRS. Wolf W Pharm Res; 2011 Mar; 28(3):490-3. PubMed ID: 20886263 [No Abstract] [Full Text] [Related]
59. When reversible ligands do not reverse, and other modelers' dilemmas. Slifstein M J Nucl Med; 2010 Jul; 51(7):1005-8. PubMed ID: 20554739 [No Abstract] [Full Text] [Related]
60. Perspectives on nuclear chemistry, radiochemistry, PET/SPECT imaging and radiotherapy. Bongarzone S; Cai Z; Caillé F; Deri M; Ekoume FP; Shegani A; Radchenko V Nucl Med Biol; 2022; 112-113():66-67. PubMed ID: 36028382 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]